Principia Biopharma Inc.Company Review & Valuation

PRNB
Nasdaq
Latest Price
100.05USD
Market Capitalization
3,280.30mUSD

About Principia Biopharma Inc.

Principia Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on developing novel oral therapies for immunology and oncology in the United States. It is developing PRN1008, an inhibitor that is in Phase II clinical trial for the treatment of pemphigus, a chronic skin disease, as wellShow more as in Phase II clinical trial for the treatment of immune thrombocytopenic purpura; PRN2246, an inhibitor that is in Phase I clinical trial for the treatment of multiple sclerosis and other central nervous system diseases; PRN1371, a drug candidate, which is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has collaboration agreements with Genzyme Corporation and AbbVie Biotechnology Limited. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Show less

Industry
Biotechnology
HQ Location
South San Francisco, California

Stock Price

Price data not available for Principia Biopharma Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Kalytera Therapeutics
KalVista Pharmaceuticals
Biofrontera
Apricus Biosciences

back to top